Fmoc-Thr(tBu)-Phe-OH is a premium-grade protected dipeptide intermediate essential for solid-phase peptide synthesis (SPPS) and solution-phase peptide coupling. It plays a critical structural role as a key building block in the synthesis of NK1 (Neurokinin-1) receptor antagonists, antiemetic drug candidates, and complex active pharmaceutical ingredients (APIs) including peptide-based therapeutics.
Key Product Advantages & Features:
High Chemical & Optical Purity: HPLC purity ≥ 98.5% with strictly controlled D-enantiomer levels (chiral purity ≥ 99.5%), minimizing unwanted diastereomeric impurities during chain elongation.
Strict Residual Solvent (OVI) Control: Manufactured in full compliance with ICH Q3C guidelines. Organic Volatile Impurities (e.g., DMF, DCM, THF, ACN) are rigorously monitored and maintained well below standard pharmacopeial limits.
Enhanced Coupling Efficiency: Optimized protect group configuration ensures high solubility in standard SPPS solvents (DMF/NMP) and minimal side reactions during Fmoc deprotection.
Scalable Production Capacity: Available from gram-level analytical evaluation quantities to commercial kilogram and multi-ton supply batches.
Technical Specifications
| Parameter | Specification Standard | Test Method |
| Appearance | White to off white powder | Visual inspection |
|
Assay (HPLC) |
≥ 98.5% | HPLC-UV |
| Chiral Purity (Diastereomers) | ≤ 0.5% | Chiral HPLC |
|
Residual Solvents (OVI) |
Complies with ICH Q3C limits (DMF < 880 ppm, DCM < 600 ppm) |
GC-Headspace |
| Loss on Drying (LOD) | ≤ 1.0% | Gravimetric |
| Heavy Metals | ≤ 10 ppm | ICP-MS |
Application in NK1 Receptor Antagonist Synthesis
NK1 receptor antagonists require strict sequence integrity and stereochemical control. Fmoc-Thr(tBu)-Phe- OH serves as a pre-formed dipeptide segment that prevents racemization at the Threonine C-alpha center during peptide coupling, significantly enhancing overall yield and downstream purification efficiency.
Competitive Price
Continuous process optimization drives significant cost efficiency at every stage:
- Maximizing Output & Minimizing Waste: We boost product yield to enhance output while dramatically reducing waste.
- Strategic Sourcing: We secure cost-effective raw materials, adhering rigorously to stringent quality standards.
- Cutting Solvent Usage: Advanced recycling techniques and low-solvent synthetic pathways drastically reduce solvent consumption.
- Reducing Environmental Impact & Costs: Minimizing wastewater and byproduct generation lowers both environmental footprint and disposal expenses.
Partnering for Shared Value:
We offer discounts on bulk orders, providing substantial savings for our global clients.
Our commitment is to forge long-term, mutually beneficial partnerships where both your business and ours thrive.
By aligning our continuous innovation with your specific demands, we create powerful value that fuels shared and lasting success.
Manufacturing Site
The facility specializes in the production of key pharmaceutical intermediates and advanced metal catalysts for catalytic applications, integrating pilot-scale preparation with commercial-scale production.
Total site Area: 100,000 m² (Chemical workshop: 50,000 m²)
Annual capacity: 2200MT
FAQ
Our Certificates
Our certificates are complete and trustworthy
![L-ORNITHINE, N-[(9H-FLUOREN-9-YLMETHOXY)CARBONYL]GLYCYL-N5-[[[(2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-5-BENZOFURANYL)SULFONYL]AMINO]IMINOMETHYL]-](/uploads/43157/small/l-ornithine-n-9h-fluoren-9-ylmethoxy-carbonyl9cc77.jpg)
